PL4062913T3 - Solid oral formulation of utidelone - Google Patents

Solid oral formulation of utidelone

Info

Publication number
PL4062913T3
PL4062913T3 PL21863656.1T PL21863656T PL4062913T3 PL 4062913 T3 PL4062913 T3 PL 4062913T3 PL 21863656 T PL21863656 T PL 21863656T PL 4062913 T3 PL4062913 T3 PL 4062913T3
Authority
PL
Poland
Prior art keywords
utidelone
solid oral
oral formulation
formulation
solid
Prior art date
Application number
PL21863656.1T
Other languages
Polish (pl)
Inventor
Li Tang
Chuan Zhang
Rongguo Qiu
Original Assignee
Beijing Biostar Pharmaceuticals Co., Ltd.
Chengdu Biostar Pharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Biostar Pharmaceuticals Co., Ltd., Chengdu Biostar Pharmaceuticals, Ltd. filed Critical Beijing Biostar Pharmaceuticals Co., Ltd.
Publication of PL4062913T3 publication Critical patent/PL4062913T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL21863656.1T 2020-09-02 2021-09-02 Solid oral formulation of utidelone PL4062913T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010910072 2020-09-02
PCT/CN2021/116194 WO2022048592A1 (en) 2020-09-02 2021-09-02 Solid oral formulation of utidelone

Publications (1)

Publication Number Publication Date
PL4062913T3 true PL4062913T3 (en) 2024-07-22

Family

ID=80492210

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21863656.1T PL4062913T3 (en) 2020-09-02 2021-09-02 Solid oral formulation of utidelone

Country Status (12)

Country Link
US (1) US20230048901A1 (en)
EP (1) EP4062913B1 (en)
JP (1) JP7536098B2 (en)
KR (1) KR20230024389A (en)
CN (1) CN114727995B (en)
AU (1) AU2021337086B2 (en)
BR (1) BR112023003572A2 (en)
CA (1) CA3184960A1 (en)
ES (1) ES2981041T3 (en)
HU (1) HUE066812T2 (en)
PL (1) PL4062913T3 (en)
WO (1) WO2022048592A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024139226A1 (en) * 2022-12-27 2024-07-04 北京华昊中天生物医药股份有限公司 Pharmaceutical composition comprising albumin-bound utidelone nanoparticles and preparation method therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4319760A1 (en) * 1993-06-15 1994-12-22 Bayer Ag Ipsapiron drug preparation
ATE389401T1 (en) * 2001-01-25 2008-04-15 Bristol Myers Squibb Co METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING EPOTHILONE ANALOGS FOR CANCER TREATMENT
KR20030071853A (en) 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 Parenteral Formulations Containing Epothilone Analogs
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
EP1824458A1 (en) 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
BRPI0911482A2 (en) 2008-04-24 2017-08-29 Bristol Myers Squibb Co USE OF EPOTHYLONE D IN THE TREATMENT OF TAU-ASSOCIATED DISEASES INCLUDING ALZHEIMER DISEASES
CN101362784A (en) * 2008-10-06 2009-02-11 山东大学 Ebomycin glycosides compounds, composition using the same as activity component and use thereof
CN107041886A (en) 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 Decylization oxygen epothilone derivate preparation, the application for preparing and its treating tumour

Also Published As

Publication number Publication date
AU2021337086B2 (en) 2024-02-29
CA3184960A1 (en) 2022-03-10
JP2023508090A (en) 2023-02-28
CN114727995A (en) 2022-07-08
EP4062913A4 (en) 2023-01-18
ES2981041T3 (en) 2024-10-07
WO2022048592A1 (en) 2022-03-10
BR112023003572A2 (en) 2023-04-04
EP4062913A1 (en) 2022-09-28
KR20230024389A (en) 2023-02-20
JP7536098B2 (en) 2024-08-19
CN114727995B (en) 2024-06-11
HUE066812T2 (en) 2024-09-28
EP4062913B1 (en) 2024-05-08
US20230048901A1 (en) 2023-02-16
AU2021337086A1 (en) 2023-02-23
EP4062913C0 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
ZA201908454B (en) Solid preparation of cariprazine for oral administration
IL292682A (en) Oral formulation of x842
ZA202201541B (en) Oral formulations of edaravone and method of manufacturing thereof
EP3597175A4 (en) Oral composition capable of promoting teeth remineralization
EP3801539A4 (en) Solid oral pharmaceutical compositions of linagliptin
IL283593A (en) Oral formulations of branaplam
EP4062913C0 (en) Solid oral formulation of utidelone
IL304159A (en) Composition of bl-8040
GB201908109D0 (en) Use of oral chew
IL307482B2 (en) Application of hair-coloring compositions
EP3817738A4 (en) Compositions and methods for treatment of oral ulceration and oral mucositis
IL271658B1 (en) New oral formulations of belinostat
IL268632A (en) Solid oral formulations of amphotericin b
GB202114564D0 (en) Oral formulation
IL310652A (en) Formulations of radiprodil
EP4153140A4 (en) Oral liquid formulations of lenvatinib
IL314824A (en) Combination formulation of cedazuridine
PT3644970T (en) New oral formulations of belinostat
IL312977A (en) Formulations of pyrrolopyridine-aniline compounds
IL312073A (en) Pharmaceutical compositions of efruxifermin
IL313482A (en) Stable formulations of shr0302
ZA202205263B (en) Solid pharmaceutical forms of perampanel
GB202311981D0 (en) Oral compositions
EP3946639A4 (en) Oral care compositions and methods of use
ZA202002086B (en) Alcohol-resistant oral pharmaceutical compositions of lorazepam